Oryzon Genomics - Costs up but company remains well funded
Oryzon Genomics has reported results for H122 and highlighted the progress of key assets iadademstat and vafidemstat during the period. It reported...
668 Views
Oryzon Genomics - CRADA win to provide a halo effect
Oryzon has been awarded a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute (NCI) to develop its lead...
668 Views
Oryzon Genomics - Key milestones and extended cash runway
Oryzon is progressing with its lead assets, iadademstat and vafidemstat, in the clinic. The ALICE study continues to generate positive readouts in...
676 Views
Oryzon Genomics - Continued positive responses in ALICE trial
Oryzon presented a 42-month update of its ongoing Phase IIa ALICE trial for the treatment of acute myeloid leukaemia (AML) in newly diagnosed...
676 Views
Oryzon Genomics - FRIDA funding and orphan drug designation
Oryzon Genomics has been awarded a $2m public grant to support its ongoing Phase Ib FRIDA clinical study. This follows recent FDA approval of its...
676 Views